evoke semaglutide Novo Nordisk's oral GLP-1 drug didn't work on Alzheimer's as hoped, but don't call it a failure

Two phase 3 trials testing semaglutide in Alzheimer patients: The Evoke trials

22.15

★★★★☆4.8 (126)

Novo Nordisk says semaglutide, the drug used in Wegovy and Ozempic, does not slow Alzheimer's progression, despite early real-world signals that prompted two major Evoke trials involving more than 3,800 participants aged

20.90

★★★★★4.9 (98)

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease | Alzheimer's Research & Therapy

29.28

★★★★★5.0 (157)

CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease | NeurologyLive

25.39

★★★★★4.7 (84)

Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials

26.95

★★★★★4.9 (203)

GLP-1 receptor agonist fails to halt Alzheimer's disease

24.98

★★★★★5.0 (176)

Can Semaglutide Prevent Dementia? What the Research Says

29.88

★★★★★4.8 (132)